Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Jun. 30, 2017
Current assets:    
Cash $ 15,934 $ 8,088
Accounts receivable - trade 75 175
Work in process 0 26
Prepaid expenses and other current assets 276 283
Total Current Assets 16,285 8,572
Fixed assets, net of accumulated depreciation 25,152 25,589
Intangible assets, net of accumulated amortization 1,620 1,823
Security deposit 26 26
Total Assets 43,083 36,010
Current liabilities:    
Accounts payable (related party of $189 and $87 as of June 30, 2018 and 2017, respectively) 790 749
Accrued expenses (related party of $789 and $650 as of June 30, 2018 and 2017, respectively) 1,048 924
Capital lease obligation - current portion 197 183
Deferred revenue 0 157
Total Current Liabilities 2,035 2,013
Capital lease obligation - net of current portion 24,884 25,082
Total Liabilities 26,919 27,095
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 and 175,000,000 shares authorized as of June 30, 2018 and 2017, respectively; 16,040,126 and 8,911,851 shares issued and outstanding as of June 30, 2018 and 2017, respectively 16 9
Additional paid-in capital 104,408 81,057
Accumulated other comprehensive loss (30) (29)
Accumulated deficit (88,228) (72,123)
Total iBio, Inc. Stockholders' Equity 16,166 8,914
Noncontrolling interest (2) 1
Total Equity 16,164 8,915
Total Liabilities and Equity 43,083 36,010
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0